Fresenius Kabi introduces its first immunology biosimilar in the U.S.
CMS grants Fresenius Kabi permanent, product-specific Q-Code for IDACIO® (adalimumab-aacf)
Commitment to the development of biologic treatments across multiple therapeutic targets in immunology through an expanded pipeline
https://www.biospace.com/article/releases/idacio-adalimumab-aacf-now-available-in-the-united-states/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.